Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 2:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 31 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Linezolid IV Clear all
Terminated Phase 2 Interventional Results available

Efficacy of Oral Antibiotic Therapy Compared to Intravenous Antibiotic Therapy for Osteomyelitis

NCT02168816
View directory record Official record
Conditions
Osteomyelitis
Interventions
Intravenous Antibacterial Agent, Oral Antibacterial Agent
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 19, 2018 · Synced Oct 24, 2026, 2:58 PM EDT
Completed Phase 4 Interventional

Microbiologic Response With Linezolid And Vancomycin In Ventilator-Associated Pneumonia Due To Methicillin Resistant Staphylococcus Aureus

NCT00572559
View directory record Official record
Conditions
Pneumonia, Ventilator-Associated
Interventions
Vancomycin, Linezolid
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
36
States / cities
Phoenix, Arizona • Palm Springs, California • Rancho Mirage, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2010 · Synced Oct 24, 2026, 2:58 PM EDT
Terminated Early Phase 1 Interventional

Patients Response to Early Switch To Oral:Osteomyelitis Study

NCT02099240
View directory record Official record
Conditions
Osteomyelitis
Interventions
oral antibiotics, intravenous antibiotics
Drug · Procedure
Lead sponsor
Julio Ramirez
Other
Eligibility
18 Years to 100 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 6, 2021 · Synced Oct 24, 2026, 2:58 PM EDT
Completed Phase 2Phase 3 Interventional

Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Complicated Skin Infections

NCT01400867
View directory record Official record
Conditions
Infections, Pediatrics
Interventions
Ceftaroline fosamil, Vancomycin +/- Aztreonam or Cefazolin +/- Aztreonam, Cephalexin or Clindamycin or Linezolid
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
2 Months to 17 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
28
States / cities
Phoenix, Arizona • Orange, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2015 · Synced Oct 24, 2026, 2:58 PM EDT
Terminated Phase 2 Interventional Results available

Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults With Cancer

NCT02732327
View directory record Official record
Conditions
Neoplasms, Febrile Neutropenia
Interventions
CAZ-AVI, Vancomycin, Linezolid, Cefepime, Meropenem, Piperacillin/tazobactam
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Oct 24, 2026, 2:58 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections

NCT01339091
View directory record Official record
Conditions
Abscess, Wound Infection, Surgical Site Infection, Cellulitis
Interventions
Dalbavancin, Vancomycin / Linezolid
Drug
Lead sponsor
Durata Therapeutics Inc., an affiliate of Allergan plc
Industry
Eligibility
18 Years to 85 Years
Enrollment
573 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
55
States / cities
Anaheim, California • Azusa, California • Bellflower, California + 50 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2014 · Synced Oct 24, 2026, 2:58 PM EDT
Terminated Phase 4 Interventional Results available

Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients

NCT01734694
View directory record Official record
Conditions
Health Care Associated Pneumonia, Osteomyelitis/Septic Arthritis, Endocarditis, Bacteremia, Acute Bacterial Skin and Skin Structure Infections
Interventions
Vancomycin, Ceftaroline, Daptomycin, Linezolid
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated May 3, 2023 · Synced Oct 24, 2026, 2:58 PM EDT
Completed Phase 2 Interventional Results available

Study of Debio 1450 for Bacterial Skin Infections

NCT02426918
View directory record Official record
Conditions
Bacterial Infections
Interventions
Debio 1450 IV, Debio 1450 Oral, Linezolid, Debio 1450 Oral Placebo, Linezolid Placebo, Vancomycin IV
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
18 Years to 70 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
22
States / cities
Anaheim, California • Buena Park, California • Chula Vista, California + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Oct 24, 2026, 2:58 PM EDT
Completed Phase 3 Interventional

New Antibiotic to Treat Pediatric Patients With Infections Due to a Specific Bacteria (Vancomycin-Resistant Enterococcus)

NCT00035854
View directory record Official record
Conditions
Bacterial Infections
Interventions
Zyvox® / Linezolid
Drug
Lead sponsor
Pfizer
Industry
Eligibility
Up to 17 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
21
States / cities
Long Beach, California • Los Angeles, California • Hartford, Connecticut + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2009 · Synced Oct 24, 2026, 2:58 PM EDT
Completed Phase 3 Interventional Results available

TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections

NCT01421511
View directory record Official record
Conditions
Skin and Subcutaneous Tissue Bacterial Infections
Interventions
TR-701 FA, Linezolid
Drug
Lead sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
666 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
35
States / cities
Dothan, Alabama • Chula Vista, California • Escondido, California + 31 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2018 · Synced Oct 24, 2026, 2:58 PM EDT
Completed Phase 3 Interventional Results available

Study to Compare Delafloxacin to Moxifloxacin for the Treatment of Adults With Community-acquired Bacterial Pneumonia

NCT02679573
View directory record Official record
Conditions
Community Acquired Bacterial Pneumonia
Interventions
Delafloxacin, Moxifloxacin, Linezolid
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
860 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
25
States / cities
Montgomery, Alabama • Newark, Delaware • Coral Gables, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2020 · Synced Oct 24, 2026, 2:58 PM EDT
Completed Phase 2 Interventional Results available

Pharmacokinetics of Linezolid in Children With Cystic Fibrosis

NCT00625703
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Linezolid
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
Up to 18 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 27, 2020 · Synced Oct 24, 2026, 2:58 PM EDT
Terminated Phase 3 Interventional Results available

Study the Safety and Efficacy of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI)

NCT00865280
View directory record Official record
Conditions
Skin Diseases, Infectious
Interventions
PTK 0796, linezolid, moxifloxacin
Drug
Lead sponsor
Paratek Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
7
States / cities
Fountain Valley, California • La Mesa, California • Oceanside, California + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2021 · Synced Oct 24, 2026, 2:58 PM EDT
Completed Phase 4 Interventional

Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Complicated Community Acquired Pneumonia (CABP)

NCT01669980
View directory record Official record
Conditions
Infections, Pneumonia
Interventions
Ceftaroline fosamil, IV Ceftriaxone and Vancomycin
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
2 Months to 18 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
13
States / cities
Long Beach, California • Oakland, California • Orange County, California + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2015 · Synced Oct 24, 2026, 2:58 PM EDT
Completed Phase 2 Interventional Results available

Comparative Study To Determine The Efficacy, Safety, And Tolerability Of Ceftolozane-Tazobactam

NCT03485950
View directory record Official record
Conditions
Other Infectious Diseases
Interventions
Cefepime, Ceftolozane, Laboratory Biomarker Analysis, Meropenem, Piperacillin-Tazobactam, Tazobactam
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Oct 24, 2026, 2:58 PM EDT
Terminated Phase 2 Interventional

Safety and Efficacy of CEM-102 With Rifampin Compared to Standard Therapy in Patients With Prosthetic Joint Infections or Spacer Infection

NCT01756924
View directory record Official record
Conditions
Prosthetic Joint Infections of Hip, Prosthetic Joint Infections of Knee, Infected Spacers
Interventions
CEM-102, IV or Oral standard of care antibiotics, Rifampin
Drug
Lead sponsor
Arrevus Inc.
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
13
States / cities
Sarasota, Florida • Tamarac, Florida • Savannah, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2019 · Synced Oct 24, 2026, 2:58 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections

NCT01431339
View directory record Official record
Conditions
Abscess, Wound Infection, Surgical Site Infection, Cellulitis
Interventions
IV Dalbavancin, Vancomycin/Linezolid
Drug
Lead sponsor
Durata Therapeutics Inc., an affiliate of Allergan plc
Industry
Eligibility
18 Years to 85 Years
Enrollment
739 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
30
States / cities
Montgomery, Alabama • Anaheim, California • Buena Park, California + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2014 · Synced Oct 24, 2026, 2:58 PM EDT
Withdrawn Phase 3 Interventional

A P3 Comparator Trial in Community Acquired Bacterial Pneumonia

NCT02269644
View directory record Official record
Conditions
Community Acquired Pneumonia
Interventions
Dalbavancin, Linezolid, Linezolid Placebo, Azithromycin
Drug
Lead sponsor
Durata Therapeutics Inc., an affiliate of Allergan plc
Industry
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Butte, Montana
Source: ClinicalTrials.gov public record
Updated Jan 22, 2016 · Synced Oct 24, 2026, 2:58 PM EDT
Terminated Phase 2 Interventional Results available

Clinical Trials to Reduce the Risk of Antimicrobial Resistance

NCT01570192
View directory record Official record
Conditions
Bacterial Pneumonia
Interventions
IV meropenem, I.V. Meropenem, Parenteral aminoglycoside; tobramycin for injection USP OR gentamicin sulfate injection solution concentrate 5mg.kg IV q24h; amikacin sulfate injection USP 20 mg/kg IV q24h, Linezolid or Vancomycin (per institutional guidelines) will be available for MRSA coverage., tobramycin nebulization
Drug · Device
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
8
States / cities
San Mateo, California • Gainesville, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2017 · Synced Oct 24, 2026, 2:58 PM EDT
Terminated Phase 3 Interventional Results available

Linezolid in the Treatment of Hemodialysis Patients With Catheter-Related Gram-Positive Bloodstream Infections

NCT00108433
View directory record Official record
Conditions
Bacteremia, Gram-Positive Bacterial Infections
Interventions
Cefazolin IV, Linezolid IV, Vancomycin (IV)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
3
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 7, 2012 · Synced Oct 24, 2026, 2:58 PM EDT
Completed Phase 4 Interventional Results available

Nosocomial Pneumonia With Suspected Or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)

NCT00084266
View directory record Official record
Conditions
Methicillin Resistant Staphylococcus Aureus (MRSA)
Interventions
linezolid (Zyvox), vancomycin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
108
States / cities
Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 71 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2012 · Synced Oct 24, 2026, 2:58 PM EDT
Completed Phase 2 Interventional Results available

Study the Efficacy and Safety of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI)

NCT03716024
View directory record Official record
Conditions
Infectious Skin Disease, Bacterial Skin Disease
Interventions
PTK 0796, Linezolid
Drug
Lead sponsor
Paratek Pharmaceuticals Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
11
States / cities
Anaheim, California • Buena Park, California • Chula Vista, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2020 · Synced Oct 24, 2026, 2:58 PM EDT
Completed Phase 2 Interventional Results available

Contezolid Acefosamil Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection

NCT03747497
View directory record Official record
Conditions
Skin Diseases, Bacterial, Gram-Positive Bacterial Infections
Interventions
contezolid acefosamil, linezolid 600 mg
Drug
Lead sponsor
MicuRx
Industry
Eligibility
18 Years and older
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
7
States / cities
Chula Vista, California • La Mesa, California • Long Beach, California + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Oct 24, 2026, 2:58 PM EDT
Completed Phase 3 Interventional Results available

Omadacycline Versus Linezolid for the Treatment of ABSSSI (EudraCT #2013-003644-23)

NCT02378480
View directory record Official record
Conditions
Bacterial Infections, Skin Structures and Soft Tissue Infections
Interventions
Omadacycline, Linezolid
Drug
Lead sponsor
Paratek Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
655 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
18
States / cities
Mobile, Alabama • Chula Vista, California • La Mesa, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2019 · Synced Oct 24, 2026, 2:58 PM EDT